Targeted Lung Cancer Treatments and Eye Metastasis

Paul ZAROGOULIDIS 1; Sofia BAKA 2; Sofia LABAKI 1; George LAZARIDIS 3; Georgia TRAKADA 4

1. Pulmonary Department-Oncology Unit, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
2. Oncology Department, European Interbalkan Medical Center, Thessaloniki, Greece
3. Oncology Department, “G. Papageorgiou” University Hospital, Thessaloniki, Greece
4. Division of Pulmonology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Alexandria Hospital, Athens, Greece

ABSTRACT

Lung cancer remains the leading cause of death due to cancer. We do not have effective tools for the early detection of lung cancer, so patients are usually diagnosed at an advanced stage. However, novel therapies based on molecular pathways (such as those involving the epidermal growth factor receptor, anaplastic lymphoma kinase, serine/threonine-protein kinase B-Raf, proto-oncogene tyrosine-protein kinase ROS, c-Met proto-oncogene protein, and RET proto-oncogene protein) are now commonly used in the treatment of lung cancer. In particular, these therapies are considered as first-line treatments for non-small-cell lung cancer. This manuscript outlines previous research on these targeted treatments, focusing on whether they are effective against eye metastasis.

KEY WORDS

Lung cancer; Epidermal Growth Factor Receptor; Anaplastic Lymphoma Kinase; Serine/Threonine-Protein Kinase B-Raf; Proto-Oncogene Tyrosine-Protein Kinase ROS; C-Met Proto-Oncogene Protein; RET Proto-Oncogene Protein

©2017, Med Hypothesis Discov Innov Ophthalmol.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 3.0 License (CC BY-NC 3.0), which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Correspondence to:
Paul Zarogoulidis, M.D, PhD, Pulmonary Department-Oncology Unit, “G., Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Fax: 00302310992424, Mobile: 00306977271974, E-mail: pzaro@hotmail.com

INTRODUCTION

Lung cancer remains underdiagnosed due to the lack of early-stage symptoms. Moreover, there are no blood markers for the early detection of lung cancer (unlike for cancers such as prostate, colorectal, and gynecological cancers) (1). In the past, non-specific cytotoxic agents were the first choice of treatment for patients with stage IV non-small-cell lung cancer (NSCLC; either adenocarcinoma or squamous cell carcinoma) (2, 3). However, in the last decade, novel molecular pathways have been found to be involved in adenocarcinoma and squamous cell carcinoma of the lung, and, as a result, targeted treatments are now being used. The most important of these are the treatments that target the epidermal growth factor receptor (EGFR), anaplastic...
lymphoma kinase (ALK), serine/threonine-protein kinase B-Raf (BRAF), proto-oncogene tyrosine-protein kinase ROS (which is encoded by the ROS1 gene), c-Met proto-oncogene protein (which is encoded by the MET gene), and RET proto-oncogene protein (which is encoded by the RET gene found on chromosome 10) (4, 5). An issue that has yet to be clarified is whether these targeted treatments are effective against eye metastasis. This issue is discussed in the following section, which is based on data that were obtained via a search of the US National Center for Biotechnology Information’s PubMed service on February 19, 2017.

Overview of the Use of Targeted Treatments in Relation to Eye Metastasis

Currently, oral tyrosine kinase inhibitors (TKIs) are being used to treat EGFR- and ALK-positive patients. In particular, for EGFR-positive patients, erlotinib, gefitinib, and afatinib (the first two of which are first-generation TKIs that target EGFR, and the third of which is a second-generation TKI that targets EGFR) are the treatments of choice. If an EGFR-positive patient being treated with TKI experiences a relapse (as assessed using the Response Evaluation Criteria In Solid Tumors (RECIST) (6)), a biopsy should be performed (7). However, if the patient’s condition does not allow for a biopsy, a liquid biopsy should be performed (8). In particular, if the EGFR T790M mutation is detected, osimertinib (a TKI that targets EGFR) should be administered (9).

Research indicates that gefitinib could be an effective agent against choroidal metastasis, and it should be used if such a metastasis exists (10). In the case of brain metastasis, research indicates that afatinib may be effective as a first-line treatment (11). Furthermore, a recent study showed that osimertinib was rapidly effective against brain metastasis, and it negated the need for radiotherapy (12).

Regarding patients with ALK mutations, crizotinib (a TKI that targets ALK) is used as the first-line treatment (13). In particular, crizotinib has been shown to be effective against uveal and choroidal metastasis (14, 15). The human epidermal growth factor receptor 2 (HER2) has been found to be overexpressed in patients with lung cancer (16) and, in these cases, trastuzumab (a monoclonal antibody that targets HER2) may be administered (17). Research has indicated that this drug is able to control ocular metastasis (18). However, it is important to take into consideration that fact that trastuzumab can also induce adverse ocular effects (19).

In addition to ALK mutations, BRAF mutations have been observed in patients with lung cancer (20). In these cases, the patients could be treated with ipilimumab (a monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)). In particular, ipilimumab has been successfully used for uveal metastasis (20-24). However, orbital myositis and retinopathy have been observed in patients treated with ipilimumab (22, 23), and other immunotherapies such as nivolumab and pembrolizumab (both of which are monoclonal antibodies that target programmed cell death protein 1 (PD-1)) are currently being tested (20, 21).

In some patients with lung cancer, the ROS1 pathway has been found to be upregulated (25). In these cases, crizotinib should be administered (26). Furthermore, research has indicated that eye metastasis that involves ROS1 upregulation can be efficiently controlled with crizotinib (14). Alternatively, cabozantinib (a TKI that targets c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2)) can be used in cases involving crizotinib resistance (27).

The RET pathway has also been found to be upregulated in some patients with lung cancer (25). In these cases, crizotinib (a TKI that targets ALK and ROS1) or alectinib (a TKI that targets ALK) should be administered (28, 29, 30). Cabozantinib may also be effective (31).

Lastly, the c-Met pathway has been also shown to be upregulated in some patients with lung cancer (32). Furthermore, a previous study has suggested that, in patients with melanoma, c-Met overexpression is associated with uveal metastasis, but more data are required to clarify this association (34). A previous study indicated that crizotinib is effective against uveal metastasis that involves the upregulation of the c-Met pathway in a melanoma model (15). However, for NSCLC, cabozantinib should be used in cases involving upregulation of the c-Met pathway (33).
DISCUSSION

Overall, the data on the use of TKIs or immunotherapy to control eye metastasis are limited. We recommend that if a patient experiences a cancer relapse, biopsies should be taken from the sites of relapse. We are currently waiting for trials with larger numbers of patients with BRAF, MET, RET, and ROS mutations. In these trials, data with the control of eye metastasis should be collected so that clear conclusions can be drawn regarding the optimum treatment approaches.

DISCLOSURE

Conflicts of Interest: None declared.

No funding or sponsorship was received for this study. All the aforementioned authors met the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have provided approval for the revised manuscript to be published.

REFERENCES

References

1. Nagpal M, Singh S, Singh P, Chauhan P, Zaidi MA. Tumor markers: A diagnostic tool. Natl J Maxillofac Surg. 2016 Jan-Jun;7(1):17-20. Review. PMID: 28163473.2.
2. Zhao W, Choi YL, Song JY, Zhu Y, Xu Q, Zhang F, Jiang L, Cheng J, Zheng G, Mao M. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. Lung Cancer. 2016 Apr;94:22-7. PMID: 26973202.
3. Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2016 Apr;10(2):113-29. Review. PMID: 26620497.
4. Domvri K, Zarogoulidis P, Darwiche K, Browning RF, Li Q, Turner JF, Kioumis I, Spryatos D, Porpodis K, Papaionnou A, Tsioula T, Freitag L, Zarogoulidis K. Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. J Cancer. 2013 Nov 23;4(9):736-54. Review. PMID: 24312144.
5. Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiriatis D, Katsikogiannis N, Kourgiantzi I, Karapantzos I, Huang H, Spryatos D. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 2013 Sep;5 Suppl 4:S389-96. Review. PMID: 24102012.
6. Kim JH. Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review. Oncotarget. 2016 Mar 22;7(12):13680-7. PMID: 26885610.
7. Zarogoulidis P, Gafa M, Huang H, Darwiche K, Rapiti A, Hohenforst-Schmidt W. Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why? Clin Transl Med. 2017 Dec;6(1):6. PMID: 28101783.
8. Remon J, Caramella C, Jovelet C, Lacroix L, Lawson A, Smalley S, Howarth K, Gale D, Green E, Plagnol V, Rosenfeld N. Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA. Annals of oncology: official journal of the European Society for Medical Oncology. 2017, under proof.
9. Sullivan I, Planchar D. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne). 2017 Jan 18;3:76. Review. PMID: 28149837.
10. Inoue M, Watanabe Y, Yamane S, Kobayashi S, Arakawa A, Tsukahara T, Kaneko T, Kadonosono K. Choroidal metastasis with adenocarcinoma of the lung treated with gefitinib. Eur J Ophthalmol. 2010 Sep-Oct;20(5):963-5. PMID: 20383850.
11. Li SH, Hsieh MH, Fang YF. Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series. Medicine (Baltimore). 2015 Oct;94(41):e1739. PMID: 26469914.
12. Koba T, Kijima T, Takimoto T, Hirata H, Naito Y, Hamaguchi M, Otsuka T, Kuroyama M, Nagatomo I, Takeda Y, Kida H, Kumanogoh A. Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports. Medicine (Baltimore). 2017 Feb;96(6):e6087. PMID: 28178168.
13. Gandhi S, Chen H, Zhao Y, Dy GK. First-line treatment of advanced ALK-positive non-small-cell lung cancer. Lung Cancer (Auckl). 2015 Sep 18;6:71-82. Review. PMID: 28210152.
14. Lu S, Azada MC, Ou SH. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient. Lung Cancer. 2015 Feb;87(2):207-9. PMID: 25558789.
TARGETED LUNG CANCER TREATMENTS AND EYE METASTASIS

19. Saleh M, Bourcier T, Noel G, Speeg-Schatz C, Gaucher D. Bilateral macular ischemia and severe visual loss following trastuzumab therapy. Acta Oncologica. 2011 Apr 1;50(3):477-8.

20. de Langen AJ, Smitt EF. Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications. Therapeutic Advances in Medical Oncology. 2016 Oct 2;1758834016670555.

21. Meierjohann S. Crosstalk signaling in targeted melanoma therapy. Cancer Metastasis Rev. 2017 Feb 14. PMID: 28197745.

22. Lecouflet M, Verschoore M, Giard C, Gohier P, Le Corre Y, Milea D, Martin L. Orbital myositis associated with ipilimumab. Annales de dermatologie et de venerologie. 2012 Dec;140(6-7):448-451.

23. Audemard A, de Raucourt S, Miocque S, Comoz F, Giraud JM, Dreno B, Bienvenu B, Rogerie MJ, Dompmartin A. Melanoma-associated retinopathy treated with ipilimumab therapy. Dermatology. 2013;227(2):146-9. PMID: 24051549.

24. Moser JC, Pulido JS, Dronca RS, McWilliams RR, Markovic SN, Mansfield AS. The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma. Melanoma research. 2015 Feb 1;25(1):59-63.

25. Reguart N, Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J. Identification of ALK, ROS1 and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients. Clinical Chemistry. 2017 Jan 1;clinchem-2016.

26. Bai DY, Zhang HP, Zhong S, Suo WH, Gao DH, Ding Y, Tu JH. Clinical utility of real-time fluorescent PCR for combined detection of anaplastic lymphoma kinase and c-ros oncogene 1 receptor tyrosine kinase in non-small cell lung cancer. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2016 Dec 23;38(12):898.

27. Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, Engelman JA, Fujita N. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clinical cancer research. 2015 Jan 1;21(1):166-74.

28. Pirker R, Filipits M. Alectinib in RET-rearranged non-small cell lung cancer-Another progress in precision medicine? Transl Lung Cancer Res. 2015 Dec;4(6):797-800. PMID: 26798590.

29. Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H. Alectinib shows potent antitumor activity against RET-rearranged non–small cell lung cancer. Molecular cancer therapeutics. 2014 Dec 1;13(12):2910-8.

30. Gerber DE, Gandhi L, Costa DB. Management and future directions in non-small cell lung cancer with known activating mutations. Am Soc Clin Oncol Educ Book. 2014:e353-65. Review. PMID: 24857124.

31. Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, Van Voorhis M, Somwar R, Smith RS, Montecalvo J, Plodkowski A, Ginsberg MS, Riely GJ, Rudin CM, Ladanyi M, Kris MG. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016 Dec;17(12):1653-1660. PMID: 27825636.

32. Feng Y, Ma PC. MET targeted therapy for lung cancer: clinical development and future directions. Lung Cancer (Auckl). 2012 Aug 9;3:53-67. Review. PMID: 28210125.

33. Neal JW, Dahlberg SE, Wakelee HA, Aisner SC, Bowden M, Huang Y, Carbone DP, Gerstner GJ, Lerner RE, Rubin JL, Owonikoko TK, Stella PJ, Steen PD, Khalid AA, Ramalingam SS; ECOG-ACRIN 1512 Investigators.. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol. 2016 Dec;17(12):1661-1671. PMID: 27825638.

34. Mallikarjuna K, Pushparaj V, Biswas J, Krishnakumar S. Expression of epithelial growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study. Current eye research. 2007 Jan 1;32(3):281-90.